United Kingdom - English - MHRA (Medicines & Healthcare Products Regulatory Agency)

alliance healthcare (distribution) ltd - alitretinoin - oral capsule - 10mg

United Kingdom - English - MHRA (Medicines & Healthcare Products Regulatory Agency)

alliance healthcare (distribution) ltd - alitretinoin - oral capsule - 30mg

Canada - English - Health Canada

glaxosmithkline inc - alitretinoin - capsule - 10mg - alitretinoin 10mg - misc. skin and mucous membrane agents

Canada - English - Health Canada

glaxosmithkline inc - alitretinoin - capsule - 30mg - alitretinoin 30mg - misc. skin and mucous membrane agents

Canada - English - Health Canada

dr. reddy's laboratories inc - alitretinoin - capsule - 10mg - alitretinoin 10mg - misc. skin and mucous membrane agents

Canada - English - Health Canada

dr. reddy's laboratories inc - alitretinoin - capsule - 30mg - alitretinoin 30mg - misc. skin and mucous membrane agents

United States - English - NLM (National Library of Medicine)

concordia pharmaceuticals inc. - alitretinoin (unii: 1ua8e65kdz) (alitretinoin - unii:1ua8e65kdz) - panretin® gel is indicated for topical treatment of cutaneous lesions in patients with aids-related kaposi’s sarcoma. panretin® gel is not indicated when systemic anti-ks therapy is required (e.g., more than 10 new ks lesions in the prior month, symptomatic lymphedema, symptomatic pulmonary ks, or symptomatic visceral involvement). there is no experience to date using panretin® gel with systemic anti-ks treatment. panretin® gel is contraindicated in patients with a known hypersensitivity to retinoids or to any of the ingredients of the product.

United Kingdom - English - MHRA (Medicines & Healthcare Products Regulatory Agency)

stiefel laboratories (uk) ltd - alitretinoin - oral capsule - 10mg

United Kingdom - English - MHRA (Medicines & Healthcare Products Regulatory Agency)

stiefel laboratories (uk) ltd - alitretinoin - oral capsule - 30mg

European Union - English - EMA (European Medicines Agency)

eisai gmbh - alitretinoin - sarcoma, kaposi - antineoplastic agents - panretin gel is indicated for the topical treatment of cutaneous lesions in patients with acquired-immune-deficiency-syndrome (aids)-related kaposi's sarcoma (ks) when:lesions are not ulcerated or lymphoedematous, and;treatment of visceral ks is not required, and;lesions are not responding to systemic antiretroviral therapy, and;radiotherapy or chemotherapy are not appropriate.